Search

Search Results

• Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

  Tat’yana Ivanovna Ionova, N.B. Bulieva, O.Yu. Vinogradova, T.A. Gritsenko, L.K. Kozlova, G.B. Kuchma, E.G. Lomaia, E.R. Machyulaitene, T.P. Nikitina, N.V. Novitskaya, A.Yu. Rodionova, E.I. Usacheva, T.V. Shneider

  206-217

  01.04.2017

• Value of Patient-Reported Outcomes in Oncohematology

  T.I. Ionova, S. Salek, Е. Оliva

  573-576

  01.10.2014

• Quality of life and symptom profile in patients with chronic myeloid leukemia receiving dasatinib as а second-line therapy due to intolerance or resistance to imatinib

  T.I. Ionova, D.A. Fedorenko, T.P. Nikitina, K.A. Kurbatova

  166-176

  01.04.2013